Cure Today

Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models

HT-KIT significantly reduces tumor burden and induces cell death in preclinical GIST models by targeting KIT mutations. Rapid tumor cell death observed within 24 hours of HT-KIT treatment, with ...
Cure Today

HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds

HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
Nasdaq

Hoth Reports Positive Preclinical Results For HT-KIT

(RTTNews) - Hoth Therapeutics, Inc. (HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, Monday announced compelling preclinical data for HT-KIT ...
Seeking Alpha

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck HOTH announces strong preclinical data for HT-KIT showing ...
Seeking Alpha

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances.
WWLP-22News

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity ...